Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.

Joy X. Jarnagin,Aparna Raj Parikh,Emily E. Van Seventer,Yojan S Shah,Islam Baiev,Amirkasra Mojtahed,Jill N. Allen,Lawrence S. Blaszkowsky,Jeffrey W. Clark,Joseph W. Franses,B. J. Giantonio,Lipika Goyal,Samuel J. Klempner,Eric Roeland,David P. Ryan,Colin D. Weekes,Giulia Siravegna,Nora Horick,Ryan B. Corcoran,Ryan D. Nipp

Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.

2021

154Background: PROs assessing quality of life (QOL) and symptoms at a single timepoint frequently correlate with clinical outcomes in patients with cancer, yet efforts to understand how longitudina...

Keywords:

Internal medicine
treatment response
Medicine
Oncology
in patient
Quality of life
Cancer
gi cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations